News | Atrial Fibrillation | April 18, 2024

Shorten the Blanking Period After Atrial Fibrillation Ablation, Experts Say

New evidence published in Heart Rhythm underpins why the blanking period should be shortened

New evidence published in Heart Rhythm underpins why the blanking period should be shortened

Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. recommend shortening the blanking period from three months to one. Graphic courtesy of Dan Musat


April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period immediately after atrial fibrillation (AF) ablation, when early occurrences of AF are thought not to predict long-term AF recurrence. Two articles and an accompanying editorial in Heart Rhythm, the official journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society, and the Pediatric & Congenital Electrophysiology Society, published by Elsevier, address the controversy and recommend shortening the blanking period.
Early recurrence of atrial tachyarrhythmia (ERAT) is commonly seen following catheter ablation of AF, with reported incidences of up to 61% in the first three months. ERAT is often attributed to transient inflammation induced by tissue damage during ablation and short-term imbalances in autonomic innervation. This forms the physiologic rationale for the accepted convention of a three-month blanking period, during which arrhythmia recurrences are presumed to be relatively benign and not indicative of treatment failure. However, this reasoning disregards valuable data regarding early arrhythmia recurrences and their potential significance.

The authors of the editorial accompanying the two articles in Heart Rhythm call for the three-month blanking period to be reconsidered and posit that it might be time to "blank the blanking period" altogether. Lead author Jonathan M. Kalman, MBBS, PhD, from the Department of Cardiology, Royal Melbourne Hospital, Australia, says, "With increasing data indicating that early AF recurrence is a predictor of late recurrence, the three-month blanking period has been called into question. Although clinical trials assessing AF ablation have traditionally defined treatment success by the time to first AF recurrence, the use of such a binary efficacy outcome lacks clinical grounding and represents an oversimplification of the impact of ablative therapy."
Lead author of the article “Defining the blanking period, using continuous ECG monitoring, after cryoballoon pulmonary vein isolation,” Dan Musat, MD, from The Valley Hospital and The Snyder Center for Comprehensive Atrial Fibrillation, Ridgewood, NJ, USA, notes, "Multiple studies have challenged the duration of the blanking period. Our study used continuous monitoring and showed that both the timing of the last ERAT episode and the burden of ERAT show congruent results; any ERAT after the first month portends a worse outcome. Our data show that the ~1/3 of patients in whom ERAT occurs and/or have a burden of >0% after the first month post-cryoballoon pulmonary vein isolation, are at significantly higher risk of long-term recurrent AF. These findings lead us to consider changing the duration of the blanking period post-AF ablation to one month from the current three months."

Co-author Suneet Mittal, MD, from The Valley Hospital and The Snyder Center for Comprehensive Atrial Fibrillation, Ridgewood, NJ, USA, adds, “Our findings also demonstrate the value of continuous long-term ECG monitoring, because information about the presence and burden of AF can help inform clinical decision-making in patients following cryoballoon pulmonary vein isolation.”

In "Early atrial fibrillation recurrence post catheter ablation: Analysis from insertable cardiac monitor in the era of optimized radiofrequency ablation," De Becker et al. also emphasize the importance of continuous monitoring. They compiled data from Close-To-Cure and Close Maze studies, encompassing 165 patients who underwent radiofrequency (RF) ablation for paroxysmal or persistent AF. All patients were implanted with an insertable cardiac monitor two to three months before ablation. The study found that patients experiencing ERAT had a substantially higher risk of late recurrence, and the burden of ERAT during the blanking period was a significant predictor.
Lead investigator Benjamin De Becker, MD, from the Cardiology Department, AZ Sint Jan, Bruges, Belgium, explains, "During the blanking period, ERAT burden and ERAT occurring during the third month are independently associated with late recurrence. ERAT occurring after 64 days post-ablation was associated with a very high risk of late recurrence in both paroxysmal and persistent AF patients, suggesting that the conventional blanking period could be shortened. A blanking period post-AF ablation is mandatory to avoid unnecessary ablation because of procedural-induced arrhythmogenicity, and to avoid the occurrence of later repermeabilization of the RF lesions, which could require further reablation. Our research proposes that a two-month post-ablation blanking period would be an acceptable trade-off, minimizing the risk of an unnecessary repeat procedure. After this two-month period, atrial tachyarrhythmia occurrence is highly predictive of subsequent recurrences."
Professor Kalman concludes, "In light of this new evidence, a more stringent interpretation of these studies' findings might be that the very notion of a blanking period should be reconsidered. We believe that these data support a recommendation to eliminate the blanking period."

For more information: https://www.hrsonline.org/

Related content:

Novel Ablation Strategy Improves Freedom from Arrhythmias in Atrial Fibrillation Patients

Renal Artery Denervation and Catheter Ablation Increased Freedom From Atrial Fibrillation

Medtronic Study Evaluating Combination of Pulmonary Vein Isolation, Renal Denervation for Atrial Fibrillation

VIDEO: New Approaches to Denervation Therapy 

Renal Artery Denervation and Catheter Ablation Increased Freedom From Atrial Fibrillation

VIDEO: Device Therapies to Treat Hypertension

SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation

Medtronic Announces Spyral HTN Global Clinical Trial Program for Renal Denervation

Medtronic Randomizes First Patients in Symplicity HTN-4

Medtronic Says its U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint

The Future of Renal Denervation Following the Failed SYMPLICITY HTN-3 Trial


Related Content

News | HRS

May 19, 2024 — A physician-initiated prospective, randomized clinical trial sponsored by the National Heart, Lung, and ...

Home May 18, 2024
Home
News | HRS

May 18, 2024 — The Heart Rhythm Society (HRS) has announced the findings of three new studies demonstrating the safety ...

Home May 18, 2024
Home
News | HRS

September 21, 2023 — Vektor Medical, developers of the only FDA-cleared technology to accurately map arrhythmias using ...

Home September 21, 2023
Home
Feature | HRS | By Melinda Taschetta-Millane

The Heart Rhythm Society (HRS) announced the full lineup of speakers and sessions, including late-breaking clinical ...

Home May 17, 2023
Home
News | HRS

May 2, 2023 — The Heart Rhythm Society (HRS) is making final preparations for its Annual Heart Rhythm Meeting, HRS2023 ...

Home May 02, 2023
Home
Feature | HRS | By Lars Thording, PhD

Hospitals in the U.S. are suffering under a debilitating post-pandemic financial and operational trauma. Ascension ...

Home August 23, 2022
Home
News | HRS

August 4, 2022 — The Heart Rhythm Society (HRS) is a professional society representing a diverse population of ...

Home August 04, 2022
Home
News | HRS

May 17, 2022 — Heart Rhythm 2022 has come to a close, and the Heart Rhythm Society has released some stats regarding ...

Home May 17, 2022
Home
Videos | HRS

Interview with Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of ...

Home May 22, 2020
Home
Feature | HRS

May 20, 2020 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of them ...

Home May 20, 2020
Home
Subscribe Now